Company: MLTX
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001821586-25-000011
Chunk: 120

Company: MoonLake Immunotherapeutics
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 8
Chunk 120
---
 (in thousands)Weighted-Average Remaining Contractual Term (in years)Awards outstanding as of January 1, 202598,3931.505,1806.73Awards exercised for the three months ended March 31, 2025(93,347)1.30Awards forfeited for the three months ended March 31, 2025(5,046)5.25Awards outstanding as of March 31, 2025————Awards exercisable as of March 31, 2025————MoonLake Immunotherapeutics 2022 Equity Incentive PlanOn April 5, 2022 (the “Effective Date”), the Company created the Equity Incentive Plan to promote and closely align the interests of employees, officers, non-employee directors and other service providers of MoonLake Immunotherapeutics and its shareholders by providing share-based compensation and other performance-based compensation.  The Equity Incentive Plan provides for the grant of options, stock appreciation rights, restricted stock units, restricted stock and other share-based awards and for incentive bonuses, which may be paid in cash, Common Shares or a combination thereof, as determined by the compensation committee of the board of directors or such other committee as designated by the board of directors to administer the Equity Incentive Plan. The Equity Incentive Plan shall remain available for the grant of awards until the 10th anniversary of the Effective Date.Equity Incentive Plan (Options)Number of OptionsWeighted-Average Exercise PriceAggregate Intrinsic Value (in thousands)Weighted-Average Remaining Contractual Term (in years)Awards outstanding as of January 1, 2025972,476$24.94$28,5888.18Awards granted for the three months ended March 31, 2025229,228$43.11Awards forfeited for the three months ended March 31, 2025(12,891)$49.01Awards outstanding as of March 31, 20251,188,813$28.19$17,1618.28Awards exercisable as of March 31, 2025431,267$13.97$11,3987.27The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period.No options were exercised for the three months ended March 31, 2025.

24

MOONLAKE IMMUNOTHERAPEUT